{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:08:56Z","timestamp":1781240936635,"version":"3.54.1"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T00:00:00Z","timestamp":1741305600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beijing Chao-Yang Hospital Clinical Research Incubation Program","award":["CYFH202313"],"award-info":[{"award-number":["CYFH202313"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01681-7","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T15:10:25Z","timestamp":1741360225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Novel targeted therapies for immunoglobulin light chain amyloidosis: latest updates from the 2024 ASH annual meeting"],"prefix":"10.1186","volume":"18","author":[{"given":"Qiling","family":"Bu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,7]]},"reference":[{"issue":"1","key":"1681_CR1","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, et al. Daratumumab-Based treatment for Immunoglobulin Light-Chain amyloidosis. N Engl J Med. 2021;385(1):46\u201358.","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"1681_CR2","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2024-205077","volume":"144","author":"E Kastritis","year":"2024","unstructured":"Kastritis E, Palladini GO, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Mollee P, Lu J, Sch\u00f6nland S, et al. Subcutaneous daratumumab (DARA)\u2009+\u2009Bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: overall survival and final major organ deterioration Progression-Free survival results from the phase 3 Andromeda study. Blood. 2024;144(Supplement 1):891.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR3","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1182\/blood-2024-202932","volume":"144","author":"E Kastritis","year":"2024","unstructured":"Kastritis E, Minnema MC, Dimopoulos M-A, Merlini G, Theodorakakou F, Fotiou D, Huart A, Belhadj Merzoug K, Golfinopoulos S, Antoniou N, et al. Efficacy and safety of daratumumab monotherapy in newly diagnosed patients with stage 3B light chain amyloidosis: A phase 2 study by the European myeloma network. Blood. 2024;144(Supplement 1):1979.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR4","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2024-208341","volume":"144","author":"TL Parker","year":"2024","unstructured":"Parker TL, Rosenthal A, Sanchorawala V, Landau HJ, Campagnaro EL, Kapoor P, Neparidze N, Girnius S, Hagen P, Scott EC, et al. Isatuximab in relapsed AL amyloidosis: results of a prospective phase II trial (SWOG S1702). Blood. 2024;144(Supplement 1):3378.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1182\/blood-2024-204700","volume":"144","author":"P Mollee","year":"2024","unstructured":"Mollee P, Huart A, Mortona O, Queru K, Leyronnas C, Stephanie H, Sidiqi H, Desport E, Vincent L, Macro M, et al. Efficacy and safety of isatuximab, Pomalidomide and dexamethasone in relapsed AL amyloidosis: interim results of the Isamyp phase 2 joint study from the IFM and ALLG. Blood. 2024;144(Supplement 1):892.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR6","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2024-203254","volume":"144","author":"E Kastritis","year":"2024","unstructured":"Kastritis E, Palladini GO, Dimopoulos M-A, Jaccard A, Merlini G, Theodorakakou F, Fotiou D, Minnema MC, Wechalekar AD, Golfinopoulos S, et al. Efficacy and safety of Belantamab Mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: an updated analysis of a phase 2 study by the European myeloma network. Blood. 2024;144(Supplement 1):1927.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1182\/blood-2024-198256","volume":"144","author":"E Lebel","year":"2024","unstructured":"Lebel E, Asherie N, Assayag M, Elias S, Grisariu S, Avni B, Kfir-Erenfeld S, Dubnikov-Sharon T, Alexander-Shani R, Bessig N, et al. Efficacy and safety of Anti-BCMA chimeric antigen receptor T-Cell (CART) for the treatment of relapsed and refractory AL amyloidosis. Blood. 2024;144(Supplement 1):894.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR8","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2024-204346","volume":"144","author":"K Shen","year":"2024","unstructured":"Shen K, Guan A, Wu Y, Sun C, Zhong L, Luo J, Li J. Venetoclax plus dexamethasone as First-Line treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study. Blood. 2024;144(Supplement 1):893.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR9","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood-2024-202713","volume":"144","author":"S Ailawadhi","year":"2024","unstructured":"Ailawadhi S, Chanan-Khan AA, Khouri J, Yannakou CK, Chen Z, Wang Y, Guo H, Wang H, Li M, Ahmad M, et al. Lisaftoclax (APG-2575) combined with novel therapeutic regimens in patients (pts) with relapsed or refractory multiple myeloma (R\/R MM) or Immunoglobulin Light-Chain (AL) amyloidosis. Blood. 2024;144(Supplement 1):1022.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1182\/blood-2024-202091","volume":"144","author":"J Fu","year":"2024","unstructured":"Fu J, Ma H, Li S, Hughes MS, Kalantarov G, Liu G, Mapara M, Lentzsch S. Development of Anti-Amyloid 11-1F4- CAR phagocytes for treatment of AL amyloidosis. Blood. 2024;144(Supplement 1):360.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR11","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1182\/blood-2024-208282","volume":"144","author":"JS Wall","year":"2024","unstructured":"Wall JS, Kennel SJ, Stuckey A, Richey T, Williams AD, Balachandran M, Hancock T, Jackson JW, Wooliver DC, Macy S, et al. Characterization of AT02 bioactivity and an assessment of its potential use as an Amyloid-Clearing therapeutic for AL amyloidosis. Blood. 2024;144(Supplement 1):4641.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1681_CR12","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1182\/blood-2024-202246","volume":"144","author":"B Qin","year":"2024","unstructured":"Qin B, Jackman AB, Li Y-C, Wang J, Qiu H, Onpaeng N, Wilkens S, Grant V, Stanfield RL, Wilson I, et al. Small molecule kinetic stabilizers reduce amyloidogenicity of free light chain proteins of diverse sequences in \u039b light chain amyloidosis. Blood. 2024;144(Supplement 1):3372.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01681-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01681-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T15:10:29Z","timestamp":1741360229000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01681-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,7]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01681-7","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,7]]},"assertion":[{"value":"30 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is not applicable for this summary.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28"}}